AUG 13·SEC EDGARLow
Tezel Ahmet sold $208K of LIVN
Tezel Ahmet (Chief Innovation Officer) sold 2,675 shares of LivaNova PLC (LIVN) at $77.74 ($0.21M total) on 2026-08-11.
StockNASDAQ · US · USDHealthcare · Medical Devices
$LIVN
LivaNova PLC
Price · $LIVNvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $877K 2 txs
Tezel Ahmet2× · $877K
10b5-1 share of filings0%
Top stories · $LIVNMore →
AUG 13·SEC EDGAR
Tezel Ahmet sold (to issuer) $669K of LIVN
Tezel Ahmet (Chief Innovation Officer) sold (to issuer) 8,589 shares of LivaNova PLC (LIVN) at $77.86 ($0.67M total) on 2026-08-11.
AUG 12·fool.com
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.
LIVN sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning LIVN (LivaNova PLC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LIVN coverage spans earnings, insider activity and technology.
In the last 30 days, LIVN insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($877K). The most active reporter was Tezel Ahmet, Chief Innovation Officer, with 2 filings.
What's driving LIVN
This is an insider open-market sale, not a 10b5-1 plan, which can modestly affect near-term sentiment but is not a fundamental catalyst by itself.
This is a routine insider sale to the issuer, not a new operating or financial catalyst.
Guidance upgrade supports earnings and revenue expectations, but the free cash flow cut and higher capex raise near-term cash-flow risk.
Guidance raise with offsetting free-cash-flow cut and a next-generation OSA PMA submission delay creates a mixed near-term setup for earnings multiple and forward cash-flow expectations.
Guidance raises and margin/FCF detail suggest improving fundamentals, but higher capex and lower FCF guidance temper near-term cash-flow upside.
alphai scores every news story that mentions LIVN with an AI model for sentiment and relevance, and aggregates insider trades from LivaNova PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $LIVN
Score
Tezel Ahmet sold $208K of LIVN
Tezel Ahmet (Chief Innovation Officer) sold 2,675 shares of LivaNova PLC (LIVN) at $77.74 ($0.21M total) on 2026-08-11.
1 min readTezel Ahmet sold (to issuer) $669K of LIVN
Tezel Ahmet (Chief Innovation Officer) sold (to issuer) 8,589 shares of LivaNova PLC (LIVN) at $77.86 ($0.67M total) on 2026-08-11.
2 min read
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.
6 min readLivaNova PLC Q2 2026 Earnings Call Summary
LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.
7 min readLivaNova Q2 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.
6 min readLivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.
7 min readWhy is LivaNova stock climbing today?
LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.
3 min readLivaNova PLC (LIVN): Results of Operations and Financial Condition
LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev
6 min read
LivaNova PLC: LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
LivaNova (Nasdaq: LIVN) reported new OSPREY study data at SLEEP 2026 showing its PolySync programming increased the cumulative apnea-hypopnea index (AHI) responder rate to 84.5% in moderate-to-severe obstructive sleep apnea patients treated with proximal hypoglossal nerve stimulation. The company said PolySync reprogramming converted most initial non-responders and improved AHI and oxygen desaturation index, with no serious treatment-emergent adverse events.
4 min readLivaNova PLC (LIVN): Submission of Matters to a Vote of Security Holders
LivaNova PLC (LIVN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. livn-20260610 0001639691 false 0001639691 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min read